Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Alexandra K. Gardino
Observed names:
A. Gardino,
A.K. Gardino,
Alexandra Gardino,
Alexandra K Gardino,
Alexandra K. Gardino,
Gardino, A. K.,
Gardino, Alexandra K.
show all 7
Institution:
Recludix Pharma (United States)
Observed institutions:
Howard Hughes Medical Institute,
Blueprint Medicines (United States),
Accent Therapeutics (United States),
Recludix Pharma (United States),
Koch Institute for Integrative Cancer Research At MIT,
Massachusetts Institute of Technology,
Brandeis University
show all 7
OpenAlex ID:
A5010167232
Works
33
Awards
1
Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks
2012
·
Michael J. Lee
, Albert S. Ye
, et al.
·
Cell
·
727
PDF
Structural determinants of 14-3-3 binding specificities and regulation of subcellular localization of 14-3-3-ligand complexes: A comparison of the X-ray crystal structures of all human 14-3-3 isoforms
2006
·
Alexandra K. Gardino
, Stephen J. Smerdon
, et al.
·
Seminars in Cancer Biology
·
332
14-3-3 proteins as signaling integration points for cell cycle control and apoptosis
2011
·
Alexandra K. Gardino
, Michael B. Yaffe
·
Seminars in Cell and Developmental Biology
·
295
A Mitotic Phosphorylation Feedback Network Connects Cdk1, Plk1, 53BP1, and Chk2 to Inactivate the G2/M DNA Damage Checkpoint
2010
·
Marcel A. T. M. van Vugt
, Alexandra K. Gardino
, et al.
·
PLoS Biology
·
257
PDF
A precision therapy against cancers driven by KIT/PDGFRA mutations
2017
·
Erica K. Evans
, Alexandra K. Gardino
, et al.
·
Science Translational Medicine
·
229
Transient Non-native Hydrogen Bonds Promote Activation of a Signaling Protein
2009
·
Alexandra K. Gardino
, Janice Villali
, et al.
·
Cell
·
115
PDF
Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors
2018
·
Yemarshet K. Gebreyohannes
, Agnieszka Wozniak
, et al.
·
Clinical Cancer Research
·
80
PDF
Functional Dynamics of Response Regulators Using NMR Relaxation Techniques
2007
·
Alexandra K. Gardino
, Dorothee Kern
·
Methods in enzymology on CD-ROM/Methods in enzymology
·
52
Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis
2019
·
Johannes Lübke
, Nicole Naumann
, et al.
·
Leukemia
·
49
PDF
The NMR Solution Structure of BeF3−-Activated Spo0F Reveals the Conformational Switch in a Phosphorelay System
2003
·
Alexandra K. Gardino
, Brian F. Volkman
, et al.
·
Journal of Molecular Biology
·
39
Segmented Transition Pathway of the Signaling Protein Nitrogen Regulatory Protein C
2009
·
Ming Lei
, Janice Velos
, et al.
·
Journal of Molecular Biology
·
34
Abstract 791: BLU-285, the first selective inhibitor of PDGFRα D842V and KIT Exon 17 mutants
2015
·
Erica K. Evans
, Brian L. Hodous
, et al.
·
Cancer Research
·
27
Blu-285, a Potent and Selective Inhibitor for Hematologic Malignancies with KIT Exon 17 Mutations
2015
·
Erica Evans
, Alexandra Gardino
, et al.
·
Blood
·
22
First Selective KIT D816V Inhibitor for Patients with Systemic Mastocytosis
2014
·
Erica K. Evans
, Brian L. Hodous
, et al.
·
Blood
·
20
Targeting kinases with precision
2018
·
Alexandra K. Gardino
, Erica K. Evans
, et al.
·
Molecular & Cellular Oncology
·
19
Efficacy of BLU-285, a novel, potent inhibitor of Exon 17 Mutant KIT and PDGFRA D842V, in patient-derived xenograft model of gastrointestinal stromal tumor (GIST).
2016
·
Yemarshet Kelemework Gebreyohannes
, Madelina-Elena Zhai
, et al.
·
Journal of Clinical Oncology
·
6
Inhibitory Effects of Midostaurin and Blu-285 on Myeloid Progenitor Cells Derived from Patients with Multi-Mutated KIT D816V+ Advanced Systemic Mastocytosis
2016
·
Mohamad Jawhar
, Nicole Naumann
, et al.
·
Blood
·
4
Highly Selective and Reversible STAT6 Inhibition Demonstrates Potential for Differentiated Efficacy and Safety Profile in Type 2 Allergic Inflammation
2025
·
P. Metz
, H. Bregman
, et al.
·
American Journal of Respiratory and Critical Care Medicine
·
3
Abstract A112: Drug discovery efforts on the RNA protein methyltransferase METTL3/METTL14
2019
·
P. Ann Boriack-Sjodin
, Alexandra K. Gardino
, et al.
·
Molecular Cancer Therapeutics
·
2
1055 REX-8756 is an oral first-in-class orthosteric STAT6 inhibitor that demonstrates efficacious potential and safety differentiation in a TH2-mediated dermatitis model
2026
·
P. Metz
, H. Bregman
, et al.
·
Journal of Investigative Dermatology
738 Oral selective STAT3 inhibitors demonstrate differentiated efficacy and safety potential in preclinical models of Th17 mediated skin inflammation
2024
·
A.K. Gardino
, N. Bifulco
, et al.
·
Journal of Investigative Dermatology
PDF
Supplementary Figure S4 from Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors
2023
·
Yemarshet K. Gebreyohannes
, Agnieszka Wozniak
, et al.
PDF
Supplementary Table S1 from Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors
2023
·
Yemarshet K. Gebreyohannes
, Agnieszka Wozniak
, et al.
Data from Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors
2023
·
Yemarshet K. Gebreyohannes
, Agnieszka Wozniak
, et al.
Supplementary Figure S3 from Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors
2023
·
Yemarshet K. Gebreyohannes
, Agnieszka Wozniak
, et al.
PDF
Show more works
View as search
Works count:
33
Citation count:
2,312
H-index:
15
I10-index:
15
Year
Topic
Type